Udall Project 2 Aim 2A&C

Description

This protocol will leverage the novel (on-label, FDA-approved) local field potential measuring capability of the Medtronic Percept™ PC DBS system to study the effects of globus pallidus internus and globus pallidus externus (GPi, GPe) DBS on: the wash-out and wash-in dynamics of motor behavior and local field potentials (LFPs) and correlations between fluctuations in gait and LFPs during activities of daily living (recorded over 4 weeks). These experiments will elucidate the relationships between GP LFPs oscillations, lower limb function, postural control and gait performance.

Conditions

Parkinson Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

This protocol will leverage the novel (on-label, FDA-approved) local field potential measuring capability of the Medtronic Percept™ PC DBS system to study the effects of globus pallidus internus and globus pallidus externus (GPi, GPe) DBS on: the wash-out and wash-in dynamics of motor behavior and local field potentials (LFPs) and correlations between fluctuations in gait and LFPs during activities of daily living (recorded over 4 weeks). These experiments will elucidate the relationships between GP LFPs oscillations, lower limb function, postural control and gait performance.

Mechanisms and Effects of Pallidal Deep Brain Stimulation on Levodopa Resistant Motor Signs in Parkinson's Disease; Udall Project 2 Aim 2A&C

Udall Project 2 Aim 2A&C

Condition
Parkinson Disease
Intervention / Treatment

-

Contacts and Locations

Minneapolis

University of Minnesota, Minneapolis, Minnesota, United States, 55414

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Receiving DBS therapy in GP for treatment of PD
  • * Implanted with Medtronic Percept DBS system
  • * At least 3 months since initial activation of the neurostimulator
  • * history of musculoskeletal disorders that significantly affects the ability to perform the motor tasks in the specific experiment in question
  • * history of dementia or cognitive impairment
  • * other significant neurological disorder as determined by the PI
  • * post-operative complications or adverse effects (e.g. ON stimulation dystonias) that affect patient safety or confound the experiment
  • * lack of capacity to consent (as identified by UBACC)

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Minnesota,

Study Record Dates

2027-03-01